Giuseppe Penna

Staff Scientist

IRCCS Humanitas Research Hospital
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Background Up to 25–35% of women receive antibiotics (ABX) during pregnancy, but little is known about the consequences on a key mucosal interface such as the mammary gland, and on the development of the neonatal gut’s microbiota and IgA. We hypothesize that prenatal ABX negatively affect the immune functionality of mammary gland, the composition of breast milk microbiota, the development of neonatal fecal microbiota and the abundance of neonatal fecal IgA. Methods Case-control translational cohort study on women and neonates in the presence or absence ( N = 41 + 41 pairs) of exposure to prenatal ABX for at least 7 consecutive days after 32 weeks of gestation. Results We will evaluate IgA concentration in breast milk and in neonatal feces up to one year after delivery. We will also evaluate clinical parameters, neurodevelopment and the composition of the IgA-coated and uncoated fractions of breast milk and fecal microbiota by means of magnetic-activated cell sorting (MACS) coupled with shotgun metagenomics. Finally, we will measure the concentration of the chemokine CCL28 on maternal serum and breast milk, as a marker of activity of the entero-mammary pathway. Conclusions Our results might support a data-driven evaluation of breast milk immune function in women exposed to prenatal ABX. Impact Breast milk IgA and microbiota are critical to determine the positive effects of breastfeeding in infants. This research protocol will investigate breast milk IgA, microbiota, and the IgA + / IgA − fractions of neonatal fecal microbiota upon exposure to prenatal antibiotics. Fecal IgA and microbiota in infants exposed or not exposed to prenatal antibiotics will be analyzed up to 1 year after birth. This research will clarify the impact of prenatal antibiotics on the immune function of breast milk. This, in turn, might support the selective evaluation of breast milk IgA/microbiota in mothers exposed to prenatal antibiotics, or in donor human milk.

Year:

2025

Background Abemaciclib-induced diarrhea is a relevant concern in clinical practice. Postbiotics have emerged as a promising option for managing it. Materials and Methods We conducted a retrospective-prospective, 2-group, observational study to assess the impact of the postbiotic PostbiotiX-Restore, derived by Lactobacillus paracasei CNCM I-5220, on abemaciclib-induced diarrhea in patients with hormone receptor-positive HER2-negative breast cancer. The prospective population (Postbio group) received postbiotic during the first cycle of abemaciclib, while the retrospective one received standard care (Standard group). Diarrhea grading was defined according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events. Results During the first cycle, diarrhea occurred in 78.9% of patients in the Standard cohort and 97.1% in the Postbio one, with most cases being G1-G2. Severe (G3) diarrhea was significantly less frequent in the Postbio group (0%) compared to the Standard one (7.9%; P = .029). Over the entire study period, while the grading difference was not statistically significant, G3 events were less frequent in the Postbio population (5.9%) than the Standard one (15.4%). Moreover, Postbio patients required fewer dose reductions due to diarrhea compared to the Standard group (P = .002). Notably, in the Postbio population, G1 and G2 events had short median durations (3 and 1 days, respectively) and, for the 2 patients experiencing G3 events during the second abemaciclib cycle (off postbiotic), diarrhea lasted only 1 day. Conclusions Our study demonstrates the effect of PostbiotiX-Restore in mitigating abemaciclib-induced diarrhea, resulting in reduced severity, fewer dose reductions, and shorter duration. Further exploration and validation in larger cohorts are needed.

Year:

2024

Year:

2024

Year:

2024

Tumor resident microbiota is an emerging component of the tumor microenvironment with unclear biological function. Among all microorganisms harbored within tumor tissue, bacteria are currently the most studied due to their ability to interact with the host. To date, the tumor microbiome is reported as composed of tumor type-specific bacteria, commonly found within host cells, which can affect tumor biology as well as play a role in cancer formation, progression, and response to therapy. So far, the contribution of intratumoral microbiota in the context of soft tissue sarcoma (STS) has been underestimated; therefore, this project aims to characterize the STS microbiota and understand if it can impair the sensitivity to chemotherapeutic regimens. STS are heterogeneous cancers with more than 100 histological subtypes, different in molecular alterations, which make its personalized therapy very complex. Thus, doxorubicin is the gold standard of chemotherapy for advanced STS but it is effective for less than 50% of patients. Doxorubicin is a natural anthracycline produced by different strains of Streptomycetaceae which exploit the toxic properties of this molecule for inter-specific competition. Hence, the hypothesis that certain bacteria developed drug-inactivating mechanisms seems evolutionarily plausible. Targeting the bacterial 16S rRNA gene through a Fluorescence in situ hybridization, we were able to detect bacteria within different histotypes of sarcoma. In addition, we analyzed the microbiome composition of sarcoma tissues and adjacent healthy tissues showing that sarcomas harbor a distinct microbiome composition. Besides, comparison of different sarcoma histotypes revealed that microbiome composition seems to be shaped according to histological features. Moreover, we isolate live bacteria harbored within sarcoma tissues. To date, isolated bacteria were mainly strictly or facultative anaerobes; thus, well adapted to live in the hypoxic environment of tumors. These bacteria gave us the opportunity to investigate their ability to interfere with chemotherapy. We exposed several sarcoma-isolated bacteria strains to doxorubicin, we found that certain bacteria strains were responsible for drug degradation. This result was confirmed with functional experiments evaluating drug toxicity after bacterial exposure. In addition, we showed in vivo that the intratumoral presence of doxorubicin-degrading bacteria is sufficient to provoke the occurrence of chemoresistance in a doxorubicin-sensitive mouse model of fibrosarcoma. This study offers new insights about the relationship between the intratumoral microbiota and the occurrence of chemoresistance in cancer therapies, suggesting that microbial communities hosted within the tumor should be deeply investigated, and then manipulated, to improve the outcome of therapies. Citation Format: Luca Tiraboschi, Daniele Braga, Alessia Melacarne, Valentina Ferrari, Gerlanda Vella, Alessandro Mozzarelli, Antonino Lo Cascio, Giulia Fornasa, Michela Lizier, Sara Carloni, Giuseppe Martano, Sara Timo, Alessandro Bernardinello, Salvatore Lorenzo Renne, Ferdinando Cananzi, Alessia Bertuzzi, Giuseppe Penna, Maria Rescigno. Unveiling the impact of intratumoral microbiota in the treatment efficacy of soft tissue sarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1277.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (3)

Maria Rescigno

Professor

Humanitas University

ITALY
View details

Rita De Sanctis

Humanitas University

ITALY
View details

LUIGI BONI

Professor of Surgery - Chief of Department

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

ITALY
View details